BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31238511)

  • 1. Raman Evidence of p53-DBD Disorder Decrease upon Interaction with the Anticancer Protein Azurin.
    Signorelli S; Cannistraro S; Bizzarri AR
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin.
    De Grandis V; Bizzarri AR; Cannistraro S
    J Mol Recognit; 2007; 20(4):215-26. PubMed ID: 17703463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Characterization of the Intrinsically Disordered Protein p53 Using Raman Spectroscopy.
    Signorelli S; Cannistraro S; Bizzarri AR
    Appl Spectrosc; 2017 May; 71(5):823-832. PubMed ID: 27340212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural characteristics of the hydrophobic patch of azurin and its interaction with p53: a site-directed spin labeling study.
    Xu C; Yin J; Zhao B
    Sci China Life Sci; 2010 Oct; 53(10):1181-8. PubMed ID: 20953940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.
    Bizzarri AR; Santini S; Coppari E; Bucciantini M; Di Agostino S; Yamada T; Beattie CW; Cannistraro S
    Int J Nanomedicine; 2011; 6():3011-9. PubMed ID: 22162658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does azurin bind to the transactivation domain of p53? A Trp phosphorescence study.
    Gabellieri E; Bucciantini M; Stefani M; Cioni P
    Biophys Chem; 2011 Dec; 159(2-3):287-93. PubMed ID: 21885181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined atomic force microscopy imaging and docking study to investigate the complex between p53 DNA binding domain and Azurin.
    Bizzarri AR; Di Agostino S; Andolfi L; Cannistraro S
    J Mol Recognit; 2009; 22(6):506-15. PubMed ID: 19642109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin.
    Santini S; Bizzarri AR; Cannistraro S
    J Mol Recognit; 2011; 24(6):1043-55. PubMed ID: 22038811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of azurin and C-terminal domain of p53 is mediated by nucleic acids.
    Xu C; Zhao Y; Zhao B
    Arch Biochem Biophys; 2010 Nov; 503(2):223-9. PubMed ID: 20800053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of the anticancer p28 peptide with p53-DBD as studied by fluorescence, FRET, docking and MD simulations.
    Bizzarri AR; Moscetti I; Cannistraro S
    Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):342-350. PubMed ID: 30419285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique complex between bacterial azurin and tumor-suppressor protein p53.
    Apiyo D; Wittung-Stafshede P
    Biochem Biophys Res Commun; 2005 Jul; 332(4):965-8. PubMed ID: 15913547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin.
    Taranta M; Bizzarri AR; Cannistraro S
    J Mol Recognit; 2009; 22(3):215-22. PubMed ID: 19140135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p28, a first in class peptide inhibitor of cop1 binding to p53.
    Yamada T; Christov K; Shilkaitis A; Bratescu L; Green A; Santini S; Bizzarri AR; Cannistraro S; Gupta TK; Beattie CW
    Br J Cancer; 2013 Jun; 108(12):2495-504. PubMed ID: 23736031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.
    Coppari E; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
    Int J Nanomedicine; 2014; 9():1799-813. PubMed ID: 24748790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies.
    Signorelli S; Santini S; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
    Biochim Biophys Acta Gen Subj; 2017 Apr; 1861(4):910-921. PubMed ID: 28126403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial cupredoxin azurin and its interactions with the tumor suppressor protein p53.
    Punj V; Das Gupta TK; Chakrabarty AM
    Biochem Biophys Res Commun; 2003 Dec; 312(1):109-14. PubMed ID: 14630027
    [No Abstract]   [Full Text] [Related]  

  • 17. Complete sequential 1H and 15N nuclear magnetic resonance assignments and solution secondary structure of the blue copper protein azurin from Pseudomonas aeruginosa.
    van de Kamp M; Canters GW; Wijmenga SS; Lommen A; Hilbers CW; Nar H; Messerschmidt A; Huber R
    Biochemistry; 1992 Oct; 31(42):10194-207. PubMed ID: 1420141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain.
    Krois AS; Dyson HJ; Wright PE
    Proc Natl Acad Sci U S A; 2018 Nov; 115(48):E11302-E11310. PubMed ID: 30420502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the interaction between p53 and the bacterial protein azurin by single molecule force spectroscopy.
    Taranta M; Bizzarri AR; Cannistraro S
    J Mol Recognit; 2008; 21(1):63-70. PubMed ID: 18247358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R248Q mutation--Beyond p53-DNA binding.
    Ng JW; Lama D; Lukman S; Lane DP; Verma CS; Sim AY
    Proteins; 2015 Dec; 83(12):2240-50. PubMed ID: 26442703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.